4Filed Sep 9, 8:00 PM ET

Vertex (VRTX) EVP Jasper van Grunsven Receives 8,682-Share Award

$VRTX · VERTEX PHARMACEUTICALS INC / MA

Research Summary

AI-generated summary of this SEC filing

Updated

Vertex (VRTX) EVP Jasper van Grunsven Receives 8,682-Share Award

What Happened

  • Jasper van Grunsven, an Executive Vice President at Vertex Pharmaceuticals (VRTX), was granted 8,682 restricted stock units (RSUs) on 2026-09-08. The acquisition price is listed as $0.00, meaning this is an equity award rather than a purchase.
  • These RSUs are recorded as an award (transaction code A) and do not reflect an open-market buy or sale.

Key Details

  • Transaction date: 2026-09-08; Form 4 filed: 2026-09-10 (filed two days after the transaction).
  • Amount: 8,682 RSUs acquired at $0.00 per share.
  • Vesting: Footnote F1 — the RSU award vests in installments beginning 09/08/2027.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Filing accession: 0000875320-26-000272; no late-filing flag noted in the provided data.

Context

  • RSU awards represent a promise to deliver shares (or their cash equivalent) if and when they vest; they are common forms of executive compensation and do not require immediate cash outlay by the insider.
  • Such awards are routine compensation actions and do not, by themselves, indicate insider buying or selling sentiment in the open market.